Ultrasonography in surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease

Abstract

International guidelines recommend six monthly ultrasounds as the primary surveillance tool for patients at risk of hepatocellular carcinoma (HCC). The dominant driver of liver disease in HCC surveillance populations is shifting, particularly in Europe and the United States, from chronic viral hepatitis (B or C), towards non-alcoholic fatty liver disease (NAFLD). Today, the population requiring HCC surveillance is also characterised by a high prevalence of overweight/obesity. These patient characteristics significantly impair ultrasound quality which can impede the detection of early HCC lesions. This diagnostic limitation has significant implications considering that eligibility for curative treatment depends upon the stage at which the cancer is detected. In this narrative review, we provide a comprehensive overview of the published evidence and national/international guidelines regarding ultrasound surveillance for HCC in people with NAFLD. We examine ultrasound sensitivity in this cohort for the detection of all stage and early HCC, the impact of steatosis and abdominal obesity on ultrasound performance, evidence for the addition of serum alpha-fetoprotein measurement, optimal timing of surveillance, emerging modalities for risk stratification and screening, and outline the challenges of case finding and surveillance eligibility criteria in this patient cohort. Finally, amalgamating all available evidence, we propose a pragmatic surveillance pathway for patients with NAFLD.

Keywords

Non-alcoholic / fatty liver disease / hepatocellular carcinoma / ultrasound scan / steatosis / obesity

References

[1] Kocarnik JM,Dean FE.Global Burden of Disease 2019 Cancer CollaborationCancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019.JAMA Oncol2022;8:420-44 PMCID:PMC8719276

[2] Llovet JM,Villanueva A.Hepatocellular carcinoma.Nat Rev Dis Primers2021;7:6

[3] Burton A,Driver RJ.HCC-UK/BASL/NCRAS PartnershipRegional variations in hepatocellular carcinoma incidence, routes to diagnosis, treatment and survival in England.Br J Cancer2022;126:804-14 PMCID:PMC8888669

[4] Hydes TJ,Graef S.The impact of diabetes and glucose-lowering therapies on hepatocellular carcinoma incidence and overall survival.Clin Ther2022;44:257-68

[5] UK CR. Cancer Research UK. Liver cancer incidence statistics. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/liver-cancer/incidence#ref-2 [Last accessed on 30 Mar 2023]

[6] National Cancer Institute. Cancer stat facts: liver and intrahepatic bile duct cancer, 2022. Available from: https://seer.cancer.gov/statfacts/html/livibd.html [Last accessed on 30 Mar 2023]

[7] Smittenaar CR,Stewart K.Cancer incidence and mortality projections in the UK until 2035.Br J Cancer2016;115:1147-55 PMCID:PMC5117795

[8] Burton A,Driver RJ.HCC-UK/BASL/NCRAS Partnership Steering GroupPrimary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation.JHEP Rep2021;3:100232 PMCID:PMC7966867

[9] Younossi ZM,Henry L.Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.Hepatology2015;62:1723-30

[10] Estes C,Loomba R,Sanyal AJ.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology2018;67:123-33 PMCID:PMC5767767

[11] Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of alcohol-related liver disease.J Hepatol2018;69:154-81

[12] Office for National Statistics. cancer survival by stage at diagnosis for England.; 2019. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/cancersurvivalratescancersurvivalinenglandadultsdiagnosed [Last accessed on 30 Mar 2023]

[13] De Toni EN,Fuchs M.Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study.Gut2020;69:168-76 PMCID:PMC6943246

[14] Williams R,Bellis M.Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis.Lancet2014;384:1953-97

[15] Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[16] Marrero JA,Sirlin CB.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases.Hepatology2018;68:723-50

[17] Omata M,Kokudo N.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.Hepatol Int2017;11:317-70 PMCID:PMC5491694

[18] Yu NC,Raman SS.CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis.Clin Gastroenterol Hepatol2011;9:161-7

[19] Sangiovanni A,Iavarone M.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis.Gut2010;59:638-44

[20] Andersson KL,Goldie SJ.Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis.Clin Gastroenterol Hepatol2008;6:1418-24 PMCID:PMC4340842

[21] Riazi K,Charette JH.The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2022;7:851-61

[22] Vernon G,Younossi ZM.Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.Aliment Pharmacol Ther2011;34:274-85

[23] Stål P.Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.World J Gastroenterol2015;21:11077-87 PMCID:PMC4607906

[24] Targher G,Byrne CD.Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach.Lancet Gastroenterol Hepatol2021;6:578-88

[25] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.J Hepatol2020;73:202-9

[26] De A.Natural history of simple steatosis or nonalcoholic fatty liver.J Clin Exp Hepatol2020;10:255-62 PMCID:PMC7212297

[27] Singh S,Wang Z,Murad MH.Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol2015;13:643-54.e1 PMCID:PMC4208976

[28] Dulai PS,Patel J.Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.Hepatology2017;65:1557-65

[29] Ekstedt M,Nasr P.Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.Hepatology2015;61:1547-54

[30] Baratta F,Angelico F.Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study.Clin Gastroenterol Hepatol2020;18:2324-2331.e4

[31] Association for the Study of the Liver. Electronic address: [e-mail], Clinical Practice Guideline Panel, Chair:, EASL Governing Board representative:, Panel members:. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.J Hepatol2021;75:659-89

[32] Mózes FE,Selvaraj EA.LITMUS InvestigatorsDiagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.Gut2022;71:1006-19 PMCID:PMC8995830

[33] Dietrich CF,Berzigotti A.EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version).Ultraschall Med2017;38:e16-47

[34] Singh S,Loomba R.Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis.Eur Radiol2016;26:1431-40 PMCID:PMC5051267

[35] Lee JY,Nam CM.Incident hepatocellular carcinoma risk in patients treated with a sulfonylurea: a nationwide, nested, case-control study.Sci Rep2019;9:8532 PMCID:PMC6561966

[36] Guo B,Nima Q.China Multi-Ethnic Cohort (CMEC) collaborative groupExposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease.J Hepatol2022;76:518-25

[37] Gan T,Tong S.Air pollution and liver cancer: a systematic review.J Environ Sci (China)2023;126:817-26

[38] Pinyol R,Wang H.Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.J Hepatol2021;75:865-78

[39] Baffy G.Hepatocellular carcinoma in non-alcoholic fatty liver disease: epidemiology, pathogenesis, and prevention.J Clin Transl Hepatol2013;1:131-7 PMCID:PMC4521282

[40] Huang DQ,Kono Y,El-Serag HB.Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer.Cell Metab2022;34:969-977.e2 PMCID:PMC9762323

[41] Younossi Z,Ong JP.Global nonalcoholic steatohepatitis councilnonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates.Clin Gastroenterol Hepatol2019;17:748-755.e3

[42] Dyson J,Chattopadyhay D.Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team.J Hepatol2014;60:110-7

[43] Sanyal A,Moyneur E.Population-based risk factors and resource utilization for HCC: US perspective.Curr Med Res Opin2010;26:2183-91

[44] Orci LA,Caballol B.Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.Clin Gastroenterol Hepatol2022;20:283-292.e10

[45] Ioannou GN,Berry K.HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.J Hepatol2017:25-32 PMCID:PMC5837901

[46] Tan DJH,Lin SY.Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.Lancet Oncol2022;23:521-30 PMCID:PMC9718369

[47] Stine JG,Zimmet A.Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.Aliment Pharmacol Ther2018;48:696-703 PMCID:PMC7495494

[48] Liu YL,Leathart JB.Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.J Hepatol2014;61:75-81

[49] Hydes TJ,Kumar V.P21 Lack of NAFLD-related HCC surveillance may explain more advanced stage at diagnosis and worse median survival. BASL annual meeting..Gut2022;71:A46-A47

[50] Zhang BH,Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma.J Cancer Res Clin Oncol2004;130:417-22

[51] Singal A,Waljee A.Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.Aliment Pharmacol Ther2009;30:37-47 PMCID:PMC6871653

[52] Colli A,Casazza G.Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review.Am J Gastroenterol2006;101:513-23

[53] Yao FY,Bass NM.Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.Hepatology2001;33:1394-403

[54] Teefey SA,Dehdashti F.Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET.Radiology2003;226:533-42

[55] Gambarin-Gelwan M,Shapiro R,Min AD.Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation.Am J Gastroenterol2000;95:1535-8

[56] Tzartzeva K,Rich NE.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis.Gastroenterology2018;154:1706-1718.e1 PMCID:PMC5927818

[57] Singal AG,Narasimman M.HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis.J Hepatol2022;77:128-39 PMCID:PMC9232881

[58] Chen TH,Yen MF.Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan.Int J Cancer2002;98:257-61

[59] Simmons O,Yokoo T.Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis.Aliment Pharmacol Ther2017;45:169-77 PMCID:PMC7207219

[60] Sanyal AJ,Sargeant C.Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C.Hepatology2006;43:682-9

[61] Ascha MS,Lopez R,Feldstein AF.The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.Hepatology2010;51:1972-8

[62] Yatsuji S,Tobari M,Tokushige K.Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C.J Gastroenterol Hepatol2009;24:248-54

[63] Tang Z,Zhou X.An important approach to prolonging survival further after radical resection of AFP positive hepatocellular carcinoma. Journal of Experimental Clinical Cancer Research.J Exp Clin Cancer Res1984;3:359-66

[64] National Centre for Health Statistics. National health and nutrition examination survey, 1999-2018. Available from: https://www.cdc.gov/nchs/nhanes/index.htm [Last accessed on 30 Mar 2023]

[65] Adams LA,St Sauver J.The natural history of nonalcoholic fatty liver disease: a population-based cohort study.Gastroenterology2005;129:113-21

[66] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:73-84

[67] Poggio P,Ciccarese F.Italian Liver Cancer (ITA.LI.CA) Group.Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis.Clin Gastroenterol Hepatol2014;12:1927-33.e2

[68] Esfeh JM,Ansari-Gilani K.Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard.Clin Mol Hepatol2020;26:54-9 PMCID:PMC6940490

[69] Samoylova ML,Roberts JP.Predictors of ultrasound failure to detect hepatocellular carcinoma.Liver Transpl2018;24:1171-7

[70] Kim DH,Choi SH.Surveillance failure in ultrasound for hepatocellular carcinoma: a systematic review and meta-analysis.Gut2022;71:212-3

[71] Aby E,Truong E,Saab S.Inadequate hepatocellular carcinoma screening in patients with nonalcoholic steatohepatitis cirrhosis.J Clin Gastroenterol2019;53:142-6

[72] Lo S,Bartlett A.Clinical features and survival of nonalcoholic fatty liver disease-related hepatocellular carcinoma.Hepatology International2016;10:S437

[73] Barbara L,Gaiani S.Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival.Hepatology1992;16:132-7

[74] Ebara M,Shinagawa T.Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients.Gastroenterology1986;90:289-98

[75] Santi V,Gramenzi A.Italian Liver Cancer (ITALI.CA) GroupSemiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival.J Hepatol2010;53:291-7

[76] Trinchet JC,Bourcier V.Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH)Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities.Hepatology2011;54:1987-97

[77] Biselli M,Gramenzi A.A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis.Br J Cancer2015;112:69-76 PMCID:PMC4453600

[78] Giannini EG,Farinati F.Italian Liver Cancer (ITALI.CA) GroupDeterminants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use.Cancer2014;120:2150-7

[79] Piscaglia F,Barchetti A.HCC-NAFLD Italian Study GroupClinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study.Hepatology2016;63:827-38

[80] Paradis V,Chelbi E.Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.Hepatology2009;49:851-9

[81] Chen JG,Chen QG.Screening for liver cancer: results of a randomised controlled trial in Qidong, China.J Med Screen2003;10:204-9

[82] Duvoux C,Decaens T.Liver Transplantation French Study GroupLiver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.Gastroenterology2012;143:986-94.e3; quiz e14

[83] Kadalayil L,Pallan L.A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer.Ann Oncol2013;24:2565-70 PMCID:PMC4023407

[84] Chernyak V,Kamaya A.Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients.Radiology2018;289:816-30 PMCID:PMC6677371

[85] Lencioni R,Bolondi L.Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma.J Hepatol2008;48:848-57

[86] Nicolau C,Vilana R.Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation.Eur Radiol2004;14:1092-9

[87] Smajerova M,Little J.Contrast-enhanced ultrasonography in the evaluation of incidental focal liver lesions: a cost-effectiveness analysis.World J Gastroenterol2016;22:8605-14 PMCID:PMC5064042

[88] Yoon JH,Lee DH.A comparison of biannual two-phase low-dose liver CT and US for HCC surveillance in a group at high risk of HCC development.Liver Cancer2020;9:503-17 PMCID:PMC7548851

[89] An JY,Cunha GM.Abbreviated MRI for hepatocellular carcinoma screening and surveillance.Radiographics2020;40:1916-31 PMCID:PMC7714535

[90] Gupta P,Patel A,Sharma V.Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis.J Hepatol2021;75:108-19

[91] Best J,Sowa JP.GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis.Clin Gastroenterol Hepatol2020;18:728-735.e4

[92] Zhu R,Xu L.Diagnostic performance of Des-γ-carboxy prothrombin for hepatocellular carcinoma: a meta-analysis.Gastroenterol Res Pract2014;2014:529314 PMCID:PMC4140125

[93] Hagiwara S,Kawasaki T.Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma.J Gastroenterol2006;41:1214-9

[94] Koyama N,Kanetsuki Y.Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.J Gastroenterol2018;53:770-9

[95] Okanoue T,Shima T.Serum levels of immunoglobulin M-free inhibitors of macrophage/CD5L as a predictive and early diagnostic marker for nonalcoholic steatohepatitis-associated hepatocellular carcinoma.Hepatol Res2022;52:998-1008

[96] Chalasani NP,Bhattacharya A.Validation of a novel multitarget blood test shows high sensitivity to detect early stage hepatocellular carcinoma.Clin Gastroenterol Hepatol2022;20:173-182.e7

[97] Lin N,Xu J.A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma.Hepatol Commun2022;6:1753-63 PMCID:PMC9234637

[98] Fan R,Sun J.aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.J Hepatol2020;73:1368-78

[99] Ioannou GN,Kerr KF.Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.J Hepatol2019;71:523-33 PMCID:PMC6702126

[100] Singal AG,Yopp AC.The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis.Am J Gastroenterol2014;109:325-34 PMCID:PMC5610907

[101] Yang J,Nahon P.PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.Int J Cancer2019;144:533-44

[102] Bianco C,Pelusi S.Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.J Hepatol2021;74:775-82 PMCID:PMC7987554

[103] Fujiwara N,Crouchet E.Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.Sci Transl Med14 PMCID:PMC9236162

[104] Singal AG,Nahon P.International Liver cancer Association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance.J Hepatol2023:S0168-8278(23)00111

[105] Hamada K,Nishino N.Shear wave elastography predicts hepatocellular carcinoma risk in hepatitis C patients after sustained virological response.PLoS One2018;13:e0195173 PMCID:PMC5909618

[106] Zhang T,Deng X.APS (age, platelets, 2d shear-wave elastography) score predicts hepatocellular carcinoma in chronic hepatitis B.Radiology2021;301:350-9

[107] Nacheva-georgieva EL,Andonov VN,Tsvetkova SB.Point shear wave elastography and 2-dimensional shear wave elastography as a non-invasive method in differentiating benign from malignant liver lesions.Gastroenterology Insights2022;13:296-304

[108] Cassinotto C,Anselme S.Diagnostic performance of attenuation to stage liver steatosis with mri proton density fat fraction as reference: a prospective comparison of three US machines.Radiology2022;305:353-61

[109] Loomba R,Patton H.AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review.Gastroenterology2020;158:1822-30 PMCID:PMC8012107

[110] LI-RADS® v2017 US Core. Available from: https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-US-Algorithm-Portrait-2017.pdf [Last accessed on 30 Mar 2023]

[111] Plaz Torres MC,Furnari M.Surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: universal or selective?.Cancers (Basel)2020;12:1422

[112] Reig M,Man NK.Should patients with NAFLD/NASH Be Surveyed for HCC?.Transplantation2019;103:39-44

[113] Sanyal AJ,Clark J.NASH Clinical Research Network (CRN)prospective study of outcomes in adults with nonalcoholic fatty liver disease.N Engl J Med2021;385:1559-69 PMCID:PMC8881985

[114] Kanwal F,Mapakshi S.Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.Gastroenterology2018;155:1828-1837.e2 PMCID:PMC6279617

[115] Newsome PN,Deeks JJ.FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.Lancet Gastroenterol Hepatol2020;5:362-73 PMCID:PMC7066580

[116] Shearer JE,Parker R,Rowe IA.The natural history of advanced chronic liver disease defined by transient elastography.Clin Gastroenterol Hepatol2023;21:694-703.e8

[117] Wong VW,Wong GL.Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.Hepatology2010;51:454-62